Please assess the completion status of the following clinical trial:

Trial Title: Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Consent~* A diagnosis of borderline personality disorder (301.83)~* All subjects will have a ZAN-BPD greater or equal to 9 at randomization.~* Males and females aged 18-45 years~* Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrollment~* Able to understand and comply with the requirements of the study~Exclusion Criteria:~* Pregnancy or lactation~* Any DSM-IV Axis I disorder not defined in the inclusion criteria. The patients with BPD may not have bipolar I disorder, schizophrenia, schizoaffective disorder, delirium, or dementia. Neither may they have current DSM-IV substance dependence.~* Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others~* Known intolerance or lack of response to quetiapine fumarate, as judged by the investigator~* Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrollment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine, and saquinavir~* Use of any of the following cytochrome P450 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids~* Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomization~* Substance or alcohol dependence at enrollment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria~* Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrollment~* Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment~* Unstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension, congestive heart failure) as judged by the investigator~* Involvement in the planning and conduct of the study~* Previous enrollment or randomization of treatment in the present study.~* Participation in another drug trial within 4 weeks prior enrollment into this study or longer in accordance with local requirements~* Unstable Diabetes Mellitus~* An absolute neutrophil count (ANC) of 1.5 x 109 per liter~* Past history of lack of response to an atypical antipsychotic medication or substantial previous side effects will be cause for exclusion.~* Any medical illness that would interfere with conduct of the study will be cause for exclusion.~* Pregnant or lactating women and women of childbearing potential not using medically accepted means of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Seroquel XR 150mg oral tablets taken daily for 8 weeks.
- 2 (Type: ACTIVE_COMPARATOR): Seroquel XR 300mg oral tablets taken daily for 8 weeks.
- 3 (Type: PLACEBO_COMPARATOR): Equivalent number of placebo oral tablets taken daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete